LLY
Lilly’s shopping spree isn’t slowing down
Eli Lilly is back with another deal, and this time the checkout line runs through Ajax Therapeutics. The company says it has a definitive agreement to acquire Ajax, a biotech building next-gen JAK inhibitors for blood cancers like myelofibrosis and polycythemia vera.
Why this one matters
Ajax’s lead asset, AJ1-11095, is a first-in-class Type II JAK2 inhibitor. That’s biotech-speak for “this could be meaningfully different from what’s already out there” — the kind of line that makes investors perk up and scientists squint.
If the program works, Lilly could get a deeper, longer-lasting disease-control shot in myeloproliferative neoplasms, which is exactly the sort of niche where big pharma likes to buy its way into future growth.
The catch, because there’s always a catch
The asset is still in Phase 1, and first proof-of-concept data isn’t expected until later in 2026. So this is not a victory lap. It’s more like Lilly paying for a front-row seat before the main act even starts.
That means the market will care less about the headline and more about what comes next:
- can AJ1-11095 show clean, durable data?
- does it look better than approved therapies?
- and did Lilly just buy a future blockbuster, or a very expensive science project?
Big picture
This is classic Lilly: keep stacking assets in high-value therapeutic areas while the company’s already got investor attention from its obesity and diabetes franchise. Big pharma doesn’t stop at one hot area when there’s another pipeline lane it can merge into.